Bellicum Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLCM research report →
Companywww.bellicum.com
Bellicum Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.
- CEO
- David M. Maggio
- IPO
- 2014
- Employees
- 13
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $778.33K
- P/E
- -0.09
- P/S
- 0.52
- P/B
- 1.14
- EV/EBITDA
- 0.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1798.73%
- Net Margin
- -1664.87%
- ROE
- -189.12%
- ROIC
- -134.56%
Growth & Income
- Revenue
- $1.50M · -75.81%
- Net Income
- $-24,973,000 · -160.73%
- EPS
- $-0.81 · 2.41%
- Op Income
- $-26,981,000
- FCF YoY
- -11.64%
Performance & Tape
- 52W High
- $1.31
- 52W Low
- $0.06
- 50D MA
- $0.11
- 200D MA
- $0.26
- Beta
- 1.38
- Avg Volume
- 28.58K
Get TickerSpark's AI analysis on BLCM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 1,941,607 |
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 1,941,607 |
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 174,742 |
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 174,742 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 0 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 0 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 4,108,140 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 4,108,140 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 1,531,902 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 1,615,945 |
Our BLCM Coverage
We haven't published any research on BLCM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLCM Report →